Glucose is known to increase the cAMP concentration in pancreatic ( cells. To determine the mechanism by which cAMP augments insulin gene expression, we first identified the cAMP response elements (CREs) of the human insulin gene. In DNase I footprint analysis, the bacterially synthesized CRE-binding protein, CRE-BP1, protected four sites: two sites in the region upstream from the insulin core promoter, one site in the rn-st exon, and one site in the first intron. To examine the roles of those four sites, we constructed a series of DNA plasmids in which the wild-type and mutant insulin promoters were linked to the chloramphenicol acetyltransferase gene. Studies of the transcriptional activity of these plasmids after transfection into hamster insulinoma (HIT) cells showed that these four sites contributed additively to the cAMP
Insulin is a polypeptide hormone of major physiological importance in the regulation of glucose homeostasis in animals, and its biosynthesis in pancreatic f3 cells is regulated mainly by blood glucose (1, 2) . Although glucose is known to increase insulin biosynthesis at the transcriptional (3, 4) and translational (5) levels, the mechanisms are poorly understood. However, the facts that glucose increases the cAMP concentration in pancreatic 8 cells (6) and that analogues of cAMP augment insulin mRNA levels in isolated islets (7) and in insulin-secreting clonal cell lines (3, 4, 8) support the possibility that cAMP may participate in glucose-induced insulin gene expression.
The cAMP response element (CRE; TGACGTCA) was first identified as being an inducible enhancer of genes that can be transcribed in response to increased cAMP levels (9, 10) . Mutation analysis of the rat insulin I gene promoter indicated that the rat insulin promoter also contained one functional CRE (11) . cDNA clones of multiple CRE-binding proteins such as transcription factors CREB (12, 13) , CRE-BP1 (14) , and ATFs (15) have been isolated. All of these proteins have a basic amino acid cluster linked to the leucine zipper as a DNA-binding domain. Among multiple CREbinding proteins, only the function of CREB has been well analyzed, and little is known about the function of other CRE-binding proteins. Phosphorylation of CREB occurs at Ser-133 in response to an increase in the intracellular cAMP levels, and the phosphorylated form can activate transcription of the somatostatin gene (16) .
The c-jun and c-fos protooncogene products (c-Jun and c-Fos) have DNA-binding domains that are similar to that of CRE-binding proteins (17) (18) (19) . The c-Jun-c-Fos heterodimer, AP-1, binds preferentially to the phorbol 12-myristate 13-acetate response element (TGACTCA), which is very similar to the CRE (20, 21) but also has a low but detectable binding activity to the CRE (22, 23) . Furthermore, c-Jun can form a heterodimer with CRE-BP1 and bind to the CRE with high affinity (23) . These facts suggest that c-Jun may regulate transcription of genes such as that of insulin through CRE. However, so far little is known about the relationship between c-Jun and transcription of the insulin gene.
In this study, we have identified four CREs in the human insulin gene and found that these four CREs are responsible for cAMP inducibility and basal promoter activity. Furthermore, we have found that c-Jun represses the cAMP-induced and basal activities of the insulin promoter and that glucose deprivation increases the c-jun mRNA level in hamster insulinoma (HIT) cells.
MATERIALS AND METHODS
Plasmid Construction. To generate a series of chloramphenicol acetyltransferase (CAT) plasmids (pINCAT1 to pINCAT5) shown in Fig. 1A , various lengths of DNA fragments containing the human insulin gene promoter were isolated using appropriate restriction enzymes and inserted into the HindIII site of pSVOOCAT (24) using a HindIII linker. To make the plasmids containing the mutated CRE1 and CRE2 shown in Fig. 3A , the PCR and the oligonucleotidedirected mutagenesis (25) were used. To confirm that PCR products do not contain a sequence alteration at other than the desired location, we sequenced the PCR-derived constructs.
Preparation of Bacterially Expressed CRE-BP1 and DNase I Footprinting. CRE-BP1 was expressed in Escherichia coli using a T7 expression vector and purified as described (26, 27 Gene. To delineate the DNA sequences mediating cAMP inducibility, we fused the 451-base-pair (nt -339 to +112) fragment of the 5' flanking sequence or its 5' deleted fragments of the human insulin gene to the bacterial CAT gene (Fig. 1A) . Promoter activity and transcriptional regulation by * pJNCAT1
Bt2cAMP were examined by transient assays after transfection of these constructs into HIT cells (Fig. 1B) ,ug of internal control plasmid pact-p-gal DNA, in which the chicken cytoplasmic ,3-actin promoter was linked to the ,3-galactosidase gene, were transfected into HIT cells by the calcium phosphate method (28) . To examine the role of c-Jun in the insulin promoter activity, mixtures of 8 ,ug of each CAT plasmid DNA, 8 Ag of pRSV-c-jun or pRSV-MG, and 4 pg of pact-3-gal were transfected into HIT cells. In the plasmid pRSV-c-jun, the mouse c-jun cDNA was linked to the long terminal repeat of Rous sarcoma virus (29) .The control plasmid pRSV-MG was generated by joining the mouse P-globin gene with the long terminal repeat of Rous sarcoma virus. We have confirmed (30) or the cAMP inducibility. Although further deletion to nt -169 (pINCAT4) moderately decreased the basal transcriptional activity and cAMP inducibility, a 6-fold increase in CAT activity after Bt2cAMP addition was still observed. Deletion to nt -61 resulted in the almost complete loss of basal promoter activity, probably because the cis elements in the core promoter were removed, as has been reported (35) . These results suggest that multiple regions not only upstream but also downstream from nt -169 conferred the cAMP responsiveness. This differs from previous results with the rat insulin I gene that showed the presence of only one CRE between nt -177 and -184 (11). Multiple CRE-BP1-Binding Sites in the Human Insulin Gene. To identify the CRE within the human insulin gene, we did a DNase I footprint analysis using the bacterially synthesized CRE-BP1, one of the CRE-binding proteins ( Fig.  2A) . CRE-BP1 protected four regions: two sites in the region upstream of the RNA start site (CRE1; nt -221 to -195 and CRE2; nt -189 to -167), one site in the first exon (CRE3; nt +16 to +31), and one site in the first intron (CRE4; nt +57 to +73) (Fig. 2B) . Within the core of each protected region, we found a DNA sequence similar to the CRE consensus sequence (5'-TGACGTCA-3') (Fig. 2C) . The core sequence within the CRE2 (TGACGACC) is similar to the CRE of the rat insulin I gene (TGACGTCC) (11), although a 1-base difference was found.
cAMP Inducibility of the Human Insulin Gene Is Mediated by Four CREs. To find whether or not the cAMP responsiveness of the human insulin gene is dependent on the four putative CREs, we constructed mutant pINCAT1 plasmids containing the mutated CREs (Fig. 3A) . The CAT activities expressed in HIT cells by the wild-type and mutant plasmids are shown in Fig. 3B . The level of CAT activity expressed from the control plasmid pINCAT1 was increased about 10-fold by treatment with Bt2cAMP. When both CRE1 and CRE2 were disrupted (pINCAT1-ml), the degree of induction by Bt2cAMP was reduced to a 4-fold increase. Introduction of mutations into both CRE3 and CRE4 (pINCAT1-m2) also reduced the cAMP inducibility to 5-fold and resulted in a 2-fold reduction in basal promoter activity. Disruption of all four CREs (pINCAT-m3) dramatically reduced the cAMP inducibility to 2-fold. These results indicate that four CREs within the 5' region, including the first exon and first intron, additively contribute to the basal activity and cAMP responsiveness of the human insulin promoter.
Repression of Human Inslin Promoter Activity by c-Jun.
c-Jun is known to form a heterodimer with CRE-BP1 and bind to CRE. Therefore, we investigated the effects of c-Jun on human insulin promoter activity (Fig. 4) . Cotransfection of pINCAT1 and the c-Jun expression plasmid into HIT cells showed that c-Jun represses the basal activity and the cAMPinduced activity of human insulin promoter to one-third and one-tenth, respectively. To assess nonspecific effects of c-Jun on gene expression, the c-Jun expression plasmid was cotransfected into HIT cells with a control plasmid containing the long terminal repeat of Rous sarcoma virus linked to the CAT gene. No effect could be detected (data not shown). To examine whether the specific sequence in the region upstream from the core promoter is responsible for the c-Jun-induced repression, three deletion mutants (pINCAT2 to pINCAT4) of the human insulin promoter were used for cotransfection experiments. c-Jun represses the CAT activity expressed from any of these plasmids, indicating that the specific sequence in the region downstream of nt -169 or multiple sequences dispersed in the region between nt -339 and +112 mediate the c-Jun-induced repression. To investigate whether the four CREs mediate the c-Jun-induced repression, we used the point mutants of CREs for a cotransfection experiment (Fig. 5) . When we used the mutant of CRE1 and CRE2 (pINCAT1-ml), the repression of basal promoter activity by c-Jun was similar to that with wild-type promoter (pINCATi), but the repression of cAMP-induced activity by c-Jun was partially relieved, and c-Jun repressed the activity to one-eighth. Similarly, when the mutant of CRE3 and CRE4 (pINCAT-m2) was used, the c-Jun-induced repression was partially relieved. In this case, c-Jun repressed the basal promoter activity and the cAMP-induced activity to one-half and one-seventh, respectively. Disruption of all four CREs (pINCAT1-m3) strongly relieved the c-Jun-induced repression, and only slight repressions of the basal promoter activity (1.5-fold) and the cAMP-induced activity (3-fold) were observed with pINCAT1-m3. These results indicate that c-Jun represses the basal and cAMPinduced promoter activities of the human insulin gene that depends on the four CREs.
Effect of the Glucose Concentration on the c-jun mRNA Level. Glucose is known to increase insulin gene transcription, but its mechanism is poorly understood. Our results indicate that c-Jun represses the insulin gene transcription. Therefore, we examined whether glucose affected the level of c-jun expression. After culture of HIT cells for 24 h in the medium containing various glucose concentrations, the level of c-jun mRNA was analyzed on Northern blots (Fig. 6) . Two mRNA species, 2.6 and 3.2 kilobases, were detected using the mouse c-jun cDNA probe, as reported in other species (36). The c-jun mRNA level was invariable at 2.8-22.2 mM glucose but was dramatically increased about 10-fold by glucose deprivation. These results suggest that glucose deprivation causes a decrease of insulin gene expression by increasing the level of c-Jun. In addition, after 24 h of culture in the medium containing various glucose concentrations the level of insulin mRNA in HIT cells was also analyzed on Northern blots (Fig. 6C) . The insulin mRNA level in HIT cells cultured at 2.8 mM glucose was increased =3-fold compared to cells cultured without glucose. However, only a little transcriptional response to glucose was observed above the 2.8 mM glucose concentration. DISCUSSION Our results demonstrate that there are four functional CREs in the 5' region of the human insulin gene and that these four CREs contribute additively to cAMP responsiveness of the human insulin gene promoter. Within the core of each CRE, there is a sequence similar to the CRE consensus sequence and the introduction of mutations into these CRE consensus sequences results in a severe decrease in the basal and cAMP-induced promoter activity. Philippe and Missotten (11) reported that a deletion or point mutation ofthe sequence TGACGTCC between nt -177 and -184 within the rat insulin I gene promoter markedly decreased the basal activity and cAMP responsiveness, using HIT cells. The nearly identical corresponding sequence TGACGACC (nt -182 to -175) is within the CRE2 of the human insulin gene and was shown to bind to nuclear protein extracted from HIT cells (37) . However, deletion or point mutation of this element only partially impairs the basal and cAMP-induced activities of the human insulin promoter. In addition, there is little similarity between rat and human in the regions correspond-ing to CREs other than CRE2 of the human insulin gene. These facts suggest that the rat and human insulin genes have one and four CREs, respectively, and that their expressions are regulated differently by cAMP.
Our results show that c-Jun represses the basal and cAMPinduced activities of the human insulin promoter. c-Jun and c-Fos are components of the transcription factor AP-1 that recognizes the phorbol 12-myristate 13-acetate response element and activates transcription of many genes, such as the collagenase gene (20, 21) . In addition to positive regulatory effects, c-Fos has been shown to down regulate several immediate early genes, such as the c-fos gene depending on a CC(A/T)6GG (CArG) element (38) (39) (40) . The results obtained by using the c-Jun expression plasmid were in agreement; the c-Fos-induced trans-repression of the immediate early gene promoter was enhanced by c-Jun in some cases (39) , but not in other cases (40) . We observed that not only c-Jun but also c-Fos repressed the insulin promoter activity (data not shown). Since the 5' deletion to nt -169 did not relieve this c-Jun-induced repression, the DNA sequences responsible for this negative regulation seem to exist between nt -169 and + 112 of the human insulin gene. However, this region of the human insulin gene does not contain a sequence similar to the CArG element, suggesting that the mechanism of the c-Jun-or c-Fos-induced repression of the human insulin promoter is different from that described above. Recently, we have found that the CRE-BP1 homodimer binds to the CREs of the human insulin gene, but neither the c-Jun-CRE-BP1 heterodimer nor the c-Jun homodimer binds to the CREs of the human insulin gene (data not shown). These results suggest that c-Jun represses transcription of the human insulin gene by inhibiting some CRE-binding proteins such as CRE-BP1 and that this c-Jun-induced repression depends on the unique CRE sequences in the human insulin gene promoter that differ from both consensus sequences of CRE and the phorbol 12-myristate 13-acetate response element. Both the protooncogenes c-jun and c-fos are the immediate early genes whose characteristic is that their expression is low or undetectable in quiescent cells but is rapidly induced at the transcriptional level upon stimulation of cellular proliferation: serum, growth factors, or phorbol 12-myristate 13-acetate (36, 41, 42) . Interestingly, however, in HIT cells glucose deprivation greatly increased the c-jun mRNA level. Since c-Jun was observed to repress the basal and cAMP-induced activities of the human insulin promoter, c-Jun might be important in the decrease of insulin gene expression at low glucose concentrations. Although we found a 10-fold increase of the c-jun mRNA level upon glucose deprivation, the c-jun mRNA level was not changed dramatically from 2.8 to 22.2 mM glucose. Even at 2.8 mM glucose, which is =50 mg/dl and is low by physiological standards, the c-jun mRNA level was not elevated. However, the facts that in HIT cells the insulin mRNA level was low at 0 mM glucose and was increased at 2.8-22.2 mM glucose and that the c-jun mRNA level was, correspondingly, invariable at 2.8-22.2 mM glucose but was increased dramatically by glucose deprivation suggest that reduced expression of c-jun mRNA may have a role in the glucose-induced increase of insulin gene transcription. A study using primary (3 cells that respond to glucose at concentrations within the physiological range (43) will be required to clarify this point. Although further studies are necessary to clarify the relationship between c-Jun and glucose-regulated gene expression, our findings may provide a clue as to how the expression of the human insulin gene is regulated.
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